Company’s 36-month beta value is 0.42.Analysts have differing opinions on the stock, with 14 analysts rating it as a “buy,” 4 as “overweight,” 14 as “hold,” and 1 as “sell.”
The public float for VRTX is 256.00M, and currently, short sellers hold a 1.72% ratio of that floaft. The average trading volume of VRTX on June 20, 2025 was 1.69M shares.
VRTX) stock’s latest price update
The stock price of Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) has jumped by 1.45 compared to previous close of 441.99. Despite this, the company has seen a fall of -0.89% in its stock price over the last five trading days. zacks.com reported 2025-06-19 that Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
VRTX’s Market Performance
Vertex Pharmaceuticals, Inc (VRTX) has experienced a -0.89% fall in stock performance for the past week, with a 1.76% rise in the past month, and a -12.51% drop in the past quarter. The volatility ratio for the week is 1.46%, and the volatility levels for the past 30 days are at 1.27% for VRTX.. The simple moving average for the past 20 days is 0.49% for VRTX’s stock, with a -3.59% simple moving average for the past 200 days.
Analysts’ Opinion of VRTX
Leerink Partners, on the other hand, stated in their research note that they expect to see VRTX reach a price target of $503. The rating they have provided for VRTX stocks is “Market Perform” according to the report published on May 06th, 2025.
Cantor Fitzgerald gave a rating of “Overweight” to VRTX, setting the target price at $535 in the report published on April 22nd of the current year.
VRTX Trading at -2.77% from the 50-Day Moving Average
After a stumble in the market that brought VRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.75% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRTX starting from LR 2019 Benefit Trust, who proposed sale 170 shares at the price of $447.18 back on May 21 ’25. After this action, LR 2019 Benefit Trust now owns shares of Vertex Pharmaceuticals, Inc, valued at $76,021 using the latest closing price.
SR 2019 Benefit Trust, the Director of Vertex Pharmaceuticals, Inc, proposed sale 170 shares at $447.18 during a trade that took place back on May 21 ’25, which means that SR 2019 Benefit Trust is holding shares at $76,021 based on the most recent closing price.
Stock Fundamentals for VRTX
Current profitability levels for the company are sitting at:
- -0.07 for the present operating margin
- 0.86 for the gross margin
The net margin for Vertex Pharmaceuticals, Inc stands at -0.09. The total capital return value is set at -0.04. Equity return is now at value -5.64, with -4.23 for asset returns.
Based on Vertex Pharmaceuticals, Inc (VRTX), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -0.59. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is -32.0.
Currently, EBITDA for the company is 486.3 million with net debt to EBITDA at 39.65. When we switch over and look at the enterprise to sales, we see a ratio of 10.1. The receivables turnover for the company is 6.15for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.65.
Conclusion
In a nutshell, Vertex Pharmaceuticals, Inc (VRTX) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
